Cargando…

Clinicopathological characteristics correlated with programmed cell death-ligand 1 expression in advanced lung adenocarcinoma

BACKGROUND: Recent studies have shown that immune checkpoint inhibitors (ICIs) targeting programmed cell death-ligand 1 (PD-L1) have potential benefits in patients with non-small cell lung cancer (NSCLC) subgroups, while the clinicopathological characteristics associated with PD-L1 expression have n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Hengxing, Zou, Xuexue, Wang, Jing, Zhou, Jiejun, Fan, Meng, Chen, Mingwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636434/ https://www.ncbi.nlm.nih.gov/pubmed/37969280 http://dx.doi.org/10.21037/jtd-23-523

Ejemplares similares

Programmed cell death‐ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics
por: Mou, Haibo, et al.
Publicado: (2021)

Clinical characteristics and programmed cell death ligand-1 expression in adenocarcinoma in situ and minimally invasive adenocarcinoma of lung
por: Yu, Renke, et al.
Publicado: (2017)

Clinicopathologic characteristics and survival outcome in patients with advanced lung adenocarcinoma and KRAS mutation
por: Yang, Shifeng, et al.
Publicado: (2018)

Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer
por: Kim, Ji Hye, et al.
Publicado: (2020)

Correlation between Programmed Death-1 Ligand-1 and p53 in Patients with Lung Adenocarcinoma
por: Xu, Cheng, et al.
Publicado: (2018)

Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma
por: Song, Zhengbo, et al.
Publicado: (2016)

Correlation between clinicopathological characteristics of lung adenocarcinoma and the risk of venous thromboembolism
por: Zhang, Yuan, et al.
Publicado: (2021)

Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer
por: Kumar, Manish, et al.
Publicado: (2020)

The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma
por: Wu, Shafei, et al.
Publicado: (2017)

Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients
por: Li, Kang, et al.
Publicado: (2022)

Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients
por: Wang, Shuo, et al.
Publicado: (2021)

A CT-derived deep neural network predicts for programmed death ligand-1 expression status in advanced lung adenocarcinomas
por: Zhu, Ying, et al.
Publicado: (2020)

Clinicopathologic and Molecular Characteristics of Lung Adenocarcinoma Arising in Young Patients
por: Kim, Lucia, et al.
Publicado: (2012)

Analysis of the Clinicopathologic Characteristics of Lung Adenocarcinoma With CTNNB1 Mutation
por: Zhou, Chao, et al.
Publicado: (2020)

The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma
por: Zhou, Wensheng, et al.
Publicado: (2022)

A primary Ewing's sarcoma of pleura: Case report and literature review
por: Zou, Xuexue, et al.
Publicado: (2021)

Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients
por: Chen, Jun, et al.
Publicado: (2017)

Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients
por: Yun, Sumi, et al.
Publicado: (2019)

Genomic Alterations in Primary Gastric Adenocarcinomas Correlate with Clinicopathological Characteristics and Survival
por: Weiss, Marjan M., et al.
Publicado: (2004)

Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcome
por: Grosse, Claudia, et al.
Publicado: (2019)

Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies
por: Kriegsmann, Mark, et al.
Publicado: (2019)

Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers
por: Liang, Sheng-Kai, et al.
Publicado: (2021)

Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters
por: Garg, Gaurav, et al.
Publicado: (2021)

Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis
por: Guo, Yawen, et al.
Publicado: (2016)

Analysis of mutational and clinicopathologic characteristics of lung adenocarcinoma with clear cell component
por: Gu, Chang, et al.
Publicado: (2016)

Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma
por: Pal, Krishnendu, et al.
Publicado: (2022)

Correlation of PIK3CA mutation with programmed death ligand-1 (PD-L1) expression and their clinicopathological significance in colorectal cancer
por: Ahn, Ae Ri, et al.
Publicado: (2021)

Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland
por: Grosse, Alexandra, et al.
Publicado: (2019)

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
por: Zhang, Yang, et al.
Publicado: (2014)

Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis
por: Cai, Huarong, et al.
Publicado: (2020)

Study of Programmed Death Ligand 1 and EGFR/HER2 Expression in Non-Small-Cell Lung Carcinoma With a Clinicopathological Spectrum
por: Laishram, Devina, et al.
Publicado: (2021)

Infiltration of tumor‐associated macrophages is involved in tumor programmed death‐ligand 1 expression in early lung adenocarcinoma
por: Shima, Toshiyuki, et al.
Publicado: (2020)

Programmed Death Ligand-1 Testing in Adenocarcinoma Lung: A Comparative Study of Cell Block versus Biopsy
por: Shukla, Saumya, et al.
Publicado: (2023)

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
por: Iafolla, Marco A. J., et al.
Publicado: (2017)

Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis
por: Kim, Hye Min, et al.
Publicado: (2017)

Clinicopathological Features of Programmed Cell Death-ligand 1 Expression in Patients with Oral Squamous Cell Carcinoma
por: Cui, Yong-Xin, et al.
Publicado: (2020)

Association of the programmed death ligand‐1 combined positive score in tumors and clinicopathological features in esophageal cancer
por: Huang, Ziling, et al.
Publicado: (2021)

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
por: Zhang, Chen, et al.
Publicado: (2021)

Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma
por: Zhou, Xiuzhi, et al.
Publicado: (2018)

Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis
por: Zhang, Shumeng, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v0qlq1bjfii5tniv0p49is4niq